Oddo maintains its Outperform recommendation on GenSight Biologics shares and its price target of 7E.

The announcement of successive delays in the release of Luvemoq should weigh on the share price in the short term, according to the analyst "and fuel a feeling of weariness among investors".

However, for Oddo, this does not call into question "the intrinsic qualities of the company, Lumevoq and its commercial potential".

For the analyst, the company offers an attractive risk/reward profile, given the maturity of its pipeline and its discounted valuation.

' The main drawback to our investment thesis lies in the dilution associated with the next rounds of financing expected in the short and medium term", analyzes Oddo.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.